These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29167820)

  • 21. Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies.
    Huang J; Li YB; Charlebois C; Nguyen T; Liu Z; Bloemberg D; Zafer A; Baumann E; Sodja C; Leclerc S; Fewell G; Liu Q; Prabhakarpandian B; McComb S; Stanimirovic DB; Jezierski A
    Fluids Barriers CNS; 2022 Jun; 19(1):38. PubMed ID: 35650594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
    Maggs L; Cattaneo G; Dal AE; Moghaddam AS; Ferrone S
    Front Neurosci; 2021; 15():662064. PubMed ID: 34113233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
    Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H
    Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.
    Li G; Zhang Z; Cai L; Tang X; Huang J; Yu L; Wang G; Zhong K; Cao Y; Liu C; Wang Y; Tong A; Zhou L
    Oncoimmunology; 2021; 10(1):1983306. PubMed ID: 34595061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
    Chuntova P; Hou Y; Naka R; Yamamichi A; Chen T; Goretsky Y; Hatae R; Nejo T; Kohanbash G; Mende AL; Montoya M; Downey KM; Diebold D; Skinner J; Liang HE; Schwer B; Okada H
    Neuro Oncol; 2022 Feb; 24(2):259-272. PubMed ID: 34347086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.
    Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L
    Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma.
    Abbott RC; Verdon DJ; Gracey FM; Hughes-Parry HE; Iliopoulos M; Watson KA; Mulazzani M; Luong K; D'Arcy C; Sullivan LC; Kiefel BR; Cross RS; Jenkins MR
    Clin Transl Immunology; 2021; 10(5):e1283. PubMed ID: 33976881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.
    Durgin JS; Henderson F; Nasrallah MP; Mohan S; Wang S; Lacey SF; Melenhorst JJ; Desai AS; Lee JYK; Maus MV; June CH; Brem S; O'Connor RS; Binder Z; O'Rourke DM
    Front Oncol; 2021; 11():669071. PubMed ID: 34026647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.
    Luzzi S; Giotta Lucifero A; Brambilla I; Magistrali M; Mosconi M; Savasta S; Foiadelli T
    Acta Biomed; 2020 Jun; 91(7-S):18-31. PubMed ID: 32608373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models.
    Li Y; Wu H; Chen G; Wei X; Wang C; Zhou S; Huang A; Zhang Z; Zhan C; Wu Y; Ying T
    Front Oncol; 2020; 10():1117. PubMed ID: 32974124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
    Soler DC; Kerstetter-Fogle A; McCormick TS; Sloan AE
    J Neurooncol; 2022 Jan; 156(1):81-96. PubMed ID: 34825292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19].
    Chen W; Xian N; Lin S; Liao W; Chen M
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3787-3799. PubMed ID: 37805854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
    Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L
    J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
    Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
    Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells.
    Sengupta S; Katz SC; Sengupta S; Sampath P
    Cancer Lett; 2018 Oct; 433():131-139. PubMed ID: 29959057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and future perspectives of chimeric antigen receptors against glioblastoma.
    Zhang J; Siller-Farfán JA
    Immunother Adv; 2022; 2(1):ltac014. PubMed ID: 36284838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.